Cassiopeia myeloma

Author: vxbb

August undefined, 2024

WebLeo Rasche, MD, University of Arkansas for Medical Sciences, Little Rock, AR, discusses an update on the Cassiopeia trial (NCT02541383), a study which is in... WebTreatment for multiple myeloma can often help control symptoms and improve quality of life. But myeloma usually can't be cured, which means additional treatment is needed when …

Stem cell yield and transplantation in transplant-eligible newly ...

Web5 Nov 2024 · The protocol of the Cassiopeia trial included instructions of discontinuation and dose modification, when PNP grade ≥2 was observed. However, in a subset of … Web4 Jun 2024 · Daratumumab (Darzalex) plus lenalidomide (Revlimid) and dexamethasone (D-Rd) resulted in consistently deep and durable responses compared with Rd alone for patients with transplant-ineligible newly diagnosed multiple myeloma, regardless of renal function or cytogenetic risk, according to a subgroup analysis from the phase 3 MAIA trial … heliani berlato dos santos

ASCO 2024: Interim Analysis of CASSIOPEIA Trial of …

Web19 Jun 2024 · CASSIOPEIA is the first study showing the clinical benefit of daratumumab plus standard of care in transplant-eligible patients with newly diagnosed multiple … Web13 Sep 2024 · CASSIOPEIA is a two-part, open-label, randomised, phase 3 trial of patients aged 18–65 years with newly diagnosed multiple myeloma and Eastern … Web9 May 2024 · Introduction. Multiple myeloma (MM) is a neoplasm of plasma cells that presents with heterogeneous prognostic outcomes. Recent therapeutic advances, such as the introduction of immunomodulatory drugs (IMiDs), proteosome inhibitors (PIs), and anti-CD38 antibodies, have greatly improved outcomes in patients with newly diagnosed (ND) … helia hotel budapest hungary

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myelom…

CASSIOPEIA Multiple Myeloma Hub

Web15 Apr 2024 · This round table discussion organized by the International Academy for Clinical Hematology (IACH) was dedicated to the 19th annual meeting of the International Myeloma Society (IMS), which was held in Los Angeles between the 25th and 27th August 2024. After some key meetings of the discipline of the field of clinical hematology, the … Web29 Aug 2024 · The study, CASSIOPEIA, is the first study to demonstrate the clinical benefit of daratumumab plus the standard-of-care VTd in transplant-eligible newly diagnosed patients with multiple myeloma. 5 Based on the CASSIOPEIA study, the U.S. Food and Drug Administration (FDA) granted a Priority Review designation to a supplemental … evalyn perezWeb5 Nov 2024 · Daratumumab (DARA) is a CD38-targeted mAb approved for treatment of pts with RRMM. The subcutaneous (SC) formulation of DARA has a similar safety profile as intravenous DARA, with a statistically significant reduction in infusion-related reaction (IRR) rates and a considerably shorter administration duration of 5 mins. evalytics labs

"Web21 Oct 2024 · Multiple myeloma is an incurable blood cancer that starts in the bone marrow and is characterized by an excess proliferation of plasma cells. 1 Multiple myeloma is … " - Cassiopeia myeloma

Cassiopeia myeloma

Daratumumab (DARA) maintenance or observation (OBS) after …

Web25 Jun 2024 · Philippe Moreau, MD, of the University Hospital of Nantes, who presented data from part 2 of the phase 3 CASSIOPEIA trial (NCT02541383), 1 spoke with CancerNetwork® at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, regarding recent research in the field of multiple myeloma that may have a … WebDVTd: CASSIOPEIA (Transplant-eligible) DARZALEX® in relapsed or refractory multiple myeloma DRd: POLLUX For relapsed or refractory multiple myeloma, after 1 prior …

Did you know?

Web9 Jun 2024 · CASSIOPEIA is a two-part, phase III study in patients with newly diagnosed multiple myeloma who are eligible for transplantation. The combination of the anti-CD38 … Web28 Dec 2024 · Moreau P, Hulin C, Perrot A, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.

Web3 Aug 2024 · CASSIOPEIA Trial of Dara-VTd in Transplant-Eligible Myeloma EP: 9. PI-Based Combinations for Relapsed Myeloma EP: 10. Treatment of Relapsed/Refractory Myeloma: Novel Agents EP: 11. Role of... Web9 Nov 2024 · All transplant-eligible multiple myeloma patients should receive a triplet induction therapy (immunomodulatory agents, proteasome inhibitor and …

WebHigh-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) is the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma … WebHigh-risk cytogenetic abnormalities and International Staging System (ISS) disease stage III confer poor outcomes in MM pts. In the phase 3 CASSIOPEIA study, at median follow …

Web20 Aug 2024 · Recommended frontline treatment of transplant-eligible newly diagnosed multiple myeloma (MM; NDMM) includes induction therapy, high-dose melphalan and …

Web22 Jun 2024 · Subject must have documented multiple myeloma satisfying the CRAB and measurable disease as defined by: Monoclonal plasma cells in the bone marrow ≥ 10% … evalyzerWeb26 Aug 2024 · This treatment will make a huge difference to the lives of so many newly-diagnosed myeloma patients and extend remission. ... (CASSIOPEIA) show that adding … helianthemum ben fhadaWeb13 Jun 2024 · The results were taken from the randomized, open-label phase 3 CASSIOPEIA trial (NCT02541383) in patients with transplant-eligible multiple myeloma … helianthus paradoxus endangeredWeb4 Feb 2024 · 1 Introduction Multiple myeloma (MM) is the second most common hematological malignancy, with over 170 000 new diagnosis per year worldwide ( 1 ). MM usually is a symptom-producing cancer causing predominantly bone pain, pathological fractures, fatigue and infections ( 2 ). evalys neversWeb28 May 2024 · Methods: CASSIOPEIA is a 2-part, randomized, open-label, phase 3 study in TE NDMM. Pts received 4 cycles ind and 2 cycles cons with D-VTd or VTd. 886 pts who … evalyticsWeb12 Nov 2024 · Moreau, P. et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly … heliantono dan rekanWeb17 Mar 2024 · 142. Moreau P, Hulin C, Perrot A, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet … helianthal saint jean de luz tarifs